RHYTHM PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
RYTM$113.95+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | |
| · · · Three months ended September 30, · · Nine months ended September 30, | |||||||||||||
| · 2024 · 2023 · 2024 · 2023 | |||||||||||||
| Revenues: | | | | | | | | | | | | | |
| Product revenue, net | | | $33,251 | | $22,504 | | $88,296 | | $53,194 | ||||
| Total revenues | | | | 33,251 | | | 22,504 | | | 88,296 | | | 53,194 |
| Costs and expenses: | | | | | | | | | | | | | |
| Cost of sales | | | | 3,828 | | | 2,412 | | | 9,581 | | | 6,069 |
| Research and development | | | | 37,931 | | | 33,570 | | | 196,789 | | | 105,059 |
| Selling, general, and administrative | | | 35,377 | | 30,475 | | 106,174 | | 85,158 | ||||
| Total costs and expenses | | | 77,136 | | 66,457 | | 312,544 | | 196,286 | ||||
| Loss from operations | | | (43,885) | | (43,953) | | (224,248) | | (143,092) | ||||
| Other income (expense): | | | | | | ||||||||
| Other income (expense), net | | | 1,088 | | (159) | | 2,434 | | (369) | ||||
| Gain on settlement of forward contract | | | | — | | | — | | | 8,900 | | | — |
| Interest expense | | | | (5,242) | | | (3,149) | | | (15,156) | | | (9,342) |
| Interest income | | | 4,054 | | 3,466 | | 11,196 | | 10,126 | ||||
| Total other income (expense), net | | | (100) | | 158 | | 7,374 | | 415 | ||||
| Loss before income taxes | | | | (43,985) | | | (43,795) | | | (216,874) | | | (142,677) |
| Provision (benefit) for income taxes | | | | (344) | | | 368 | | | 436 | | | 368 |
| Net loss | | | $(43,641) | | $(44,163) | | $(217,310) | | $(143,045) | ||||
| Accrued dividends on convertible preferred stock | | | | (1,329) | | | — | | | (2,631) | | | — |
| Net loss attributable to common stockholders | | | $(44,970) | | $(44,163) | | $(219,941) | | $(143,045) | ||||
| | | | | | | | | | | | | | |
| Net loss per share attributable to common stockholders, basic and diluted | | | $(0.73) | | $(0.76) | | $(3.62) | | $(2.50) | ||||
| | | | | | | | | | | | | | |
| Weighted-average common shares outstanding, basic and diluted | | | | 61,219,918 | | | 57,874,960 | | | 60,793,329 | | | 57,154,803 |
| | | | | | | | | | | | | | |
| Other comprehensive loss: | | | | | | | | | | | | | |
| Net loss attributable to common stockholders | | | $(44,970) | | $(44,163) | | $(219,941) | | $(143,045) | ||||
| Foreign currency translation adjustment | | | | (602) | | | 76 | | | (975) | | | 49 |
| Unrealized (loss) gain, net on marketable securities, net of tax | | | 615 | | (175) | | 237 | | (70) | ||||
| Comprehensive loss | | | $(44,957) | | $(44,262) | | $(220,679) | | $(143,066) | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.